The significance of the contribution of RANKL/RANK in the bone microenvironment and the immune system during bone metastasis process strengthens the notion that abrogation of RANK/RANKL signaling represents a key therapeutic target for cancer therapy. The gene discussed is TNFSF11; the disease is cancer.